The best CRISPR stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
The top gene editing stocks included on this page all trade on the S&P 500, have an analyst recommendation of "Buy" or better and are sorted by year-to-date performance.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
Crispr Therapeutics stock opened the day at $53.60 after a previous close of $53.12. The latest price was $53.90 (25-minute delay). Crispr Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD271.7 million and employs 407 staff.
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.
Editas Medicine stock opened the day at $4.60 after a previous close of $4.54. The latest price was $4.66 (25-minute delay). Editas Medicine is listed on the NASDAQ, has a trailing 12-month revenue of around USD$69.4 million and employs 265 staff.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Regeneron Pharmaceuticals stock opened the day at $1,042.28 after a previous close of $1,044.66. The latest price was $1,024.09 (25-minute delay). Regeneron Pharmaceuticals is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.1 billion and employs 13,677 staff.
Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.
Cellectis stock opened the day at $1.97 after a previous close of $1.90. The latest price was $2.05 (25-minute delay). Cellectis is listed on the NASDAQ, has a trailing 12-month revenue of around USD$12.1 million and employs 216 staff.
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
Beam Therapeutics Inc stock opened the day at $23.03 after a previous close of $22.57. The latest price was $23.48 (25-minute delay). Beam Therapeutics Inc is listed on the NASDAQ, has a trailing 12-month revenue of around USD$360.9 million and employs 346 staff.
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Bluebird bio stock opened the day at $0.93 after a previous close of $0.92. The latest price was $0.91 (25-minute delay). Bluebird bio is listed on the NASDAQ, has a trailing 12-month revenue of around USD$21.7 million and employs 323 staff.
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Sangamo Therapeutics stock opened the day at $0.33 after a previous close of $0.32. The latest price was $0.32 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$18.8 million and employs 405 staff.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Check out our picks of the best ETF brokers for beginners, options trading, micro-investing and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Check out our picks of the best robo-advisors for new and experienced investors alike.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.